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The vitreoretinal interface is involved in a wide range of vitreoretinal disorders and 
separation of the posterior vitreous face from the retinal surface is an essential part 
of vitrectomy surgeries. A diverse range of enzymatic and non-enzymatic agents are 
being studied as an adjunct before or during vitrectomy to facilitate the induction of 
posterior vitreous detachment. There is a significant body of knowledge in the literature 
about different vitreolytic agents under investigation for a variety of pathologies 
involving the vitreoretinal interface which will be summarized in this review.
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INTRODuCTION
The dynamic interaction between the peripheral 
cortical vitreous and the retina is believed to 
play a significant role in different physiologic 
and pathologic processes. The exact mechanism 
of attachment between the cortical vitreous and 
the internal limiting membrane (ILM) is not fully 
understood, but it is believed that connecting 
protein molecules are responsible for the 
adhesion between vitreous collagen fibrils and 
the ILM. The vitreous cortex is more adherent 
to the retina where the ILM is thinner such as 
the vitreous base, optic nerve head, along major 
vascular arcades and around the fovea. The 
ILM increases in thickness with aging which 
may explain why posterior vitreous detachment 
(PVD) occurs more frequently in older subjects.1 
PVD is characterized by vitreous liquefaction 
and vitreoretinal separation.2 Incomplete PVD 
or anomalous vitreoretinal adhesions are the 
basic mechanisms in a variety of vitreoretinal 
pathologies (Fig. 1).3 On the other hand, there is 
increasing evidence that complete detachment 
of the vitreous may protect against a variety 
of disorders such as diabetic retinopathy4 and 
exudative age-related macular degeneration 
(AMD).5 Apparently different disorders may 
follow a common initiating event i.e. anomalous 
PVD (Fig. 1).
During vitrectomy surgery in eyes without 
PVD, the posterior hyaloid face is mechanically 
separated from the ILM and the optic nerve head 
by vitreous pic or applying passive or active 
suction.6 These maneuvers may be associated 
with complications such as iatrogenic retinal 
tears, nerve fiber layer damage and even retinal 
detachment.7 Complications of mechanical 
PVD induction are more prevalent in eyes 
with stronger vitreoretinal adhesions such as 
that of young patients. Alternative methods 
for induction of PVD have been investigated 
extensively among which pharmacologic 
separation of vitreoretinal adhesions has long 
been an attractive idea for researchers and 
clinicians.
Agents used for pharmacologic vitreolysis 
can  be  categorized  as  “enzymatic”  or 
“nonenzymatic” according to their mechanism 
of action. The majority of proposed agents for 
pharmacologic vitreolysis are enzymes which 
include but are not limited to tissue plasminogen 
activator (tPA),8 plasmin,9 microplasmin,10 
nattokinase,11 chondroitinase,12 dispase,13 and Pharmacologic Vitreolysis; Nazari et al
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hyaluronidase.14 Nonenzymatic agents used for 
induction of PVD include urea/vitreosolve and 
Arginine-Glycine-Aspartate peptides.3
Herein, we will briefly review the literature 
related to pharmacologic vitreolysis. A 
Pubmed search by key words “vitreolysis”, 
“pharmacologic vitreolysis”, “enzymatic 
vitreolysis”, “plasmin and vitrectomy”, and 
“microplasmin and vitrectomy” was performed 
and full text English articles were retrieved.
CLASSIFICATION OF VITREOLyTIC AGENTS
In a classification system proposed by Sebag,3 
vitreolytic agents have been categorized on the 
basis of their biologic effect into those which 
induce vitreous liquefaction (“liquefactants”) and 
those which induce dehiscence at the vitreoretinal 
interface (“interfactants”). Table 1 classifies 
different enzymatic and nonenzymatic agents 
on the basis of their major biologic activity.3
Pharmacologic vitreolysis classification based on biologic activity
Liquefactants (agents that liquefy the gel vitreous)
Nonspecific: tPA, plasmin, microplasmin, nattokinase, vitreosolve*
Substrate specific: chondroitinase, hyaluronidase
Interfactants (agents that alter the vitreoretinal interface)
Nonspecific: tPA, plasmin, microplasmin, nattokinase, vitreosolve*
Substrate specific: dispase, chondroitinase
RGD-peptides*
tPA, plasmin, microplasmin, nattokinase, and vitreosolve are believed to be both liquefactants and interfactants.
Table 1. Classification of pharmacologic vitreolytic agents proposed by Sebag3
*Nonenzymatic agent.
tPA, tissue plasminogen activator; RGD, Arginine-Glycine-Aspartate.
Figure 1. Diagram summarizing different pathologies arising from anomalous posterior vitreous detachment (PVD).
VMTS, vitreomacular traction syndrome; Exud: exudative; AMD, age-related macular degenerationPharmacologic Vitreolysis; Nazari et al
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Tissue Plasminogen Activator (tPA)
Tissue plasminogen activator (tPA) is a serine 
protease involved in conversion of plasminogen 
to plasmin, the main enzyme responsible for 
blood clot lysis. In a randomized study, Hesse 
et al15 compared intravitreal injection of 25 
μg tPA to balanced salt solution (BSS) before 
vitrectomy in 10 patients with proliferative 
diabetic retinopathy (PDR). They concluded that 
tPA caused disintegration of the vitreoretinal 
interface by posterior vitreous detachment, 
facilitating pars plana vitrectomy (PPV) without 
severe side effects. They also reported on 
injecting 25 μg of recombinant tPA in rabbit 
eyes. All tPA treated eyes showed vitreous cortex 
separation from the retina and the posterior 
lens surface one week after injection, while 
none of the control eyes showed PVD.8 They 
suggested that this method may be useful before 
mechanical vitrectomy.8 Although intravitreal 
tPA injection has previously been reported 
for management of subretinal hemorrhage in 
several articles, complications such as vitreous 
hemorrhage which are related to its fibrinolytic 
activity have been a main concern.16,17 Currently, 
intraocular tPA is mainly used for treatment of 
postvitrectomy fibrin formation and submacular 
hemorrhage but has not been shown to be safe 
and/or effective for other indications such as 
induction of PVD during or before vitrectomy.18
Plasmin
Plasmin is a nonspecific protease which plays an 
active role in multiple biologic processes such as 
fibrinolysis, neovascularization and activation of 
other enzymes such as matrix metalloproteinases 
(MMP).19 Furthermore, plasmin acts directly 
on fibronectin and laminin, two major proteins 
responsible for adhesion between the posterior 
hyaloid face and the ILM.9,20 Induction of PVD 
by plasmin has been accomplished in several 
animal models.9,19-24 Electron microscopic and 
electrophysiologic studies have shown no 
evidence of retinal toxicity with intravitreal 
injection of plasmin.21,24 In addition to PVD 
induction, plasmin liquefies the vitreous; the 
combination of these two effects along with its 
safety profile, make plasmin a suitable agent for 
pharmacologic vitreolysis. Intravitreal plasmin 
injection before or during vitrectomy has been 
studied in multiple case series for diabetic 
macular edema associated with a thick and 
adherent posterior hyaloid face,25 idiopathic 
and traumatic macular holes,26-28 proliferative 
diabetic retinopathy,29 diabetic tractional retinal 
detachment,30 vitreomacular traction syndrome31 
and retinopathy of prematurity.32,33
Azzolini et al25 evaluated the intraoperative 
use of plasmin for induction of PVD in eyes 
with diabetic macular edema associated 
with posterior vitreous cortex contraction. A 
volume of 0.1 to 0.2 ml containing 0.8 to 1.2 
IU of autologous plasmin was injected into the 
vitreous body 25 minutes before surgery. In 4 
out of 12 plasmin treated eyes versus one out 
of 10 control eyes, partial or complete PVD was 
detected during vitrectomy. They found no 
significant difference in final retinal thickness, 
but plasmin treated eyes had significantly better 
visual acuity. They concluded that autologous 
plasmin may be useful for induction of PVD 
and facilitation of vitrectomy surgery.
Asami et al34 injected autologous plasmin 
before vitrectomy in 10 eyes with diabetic 
macular edema without PVD and compared 
them with 10 similar controls. They performed 
ILM peeling during surgery and evaluated 
the specimens with transmission electron 
microscopy. In the plasmin treated group, 8 eyes 
showed a smooth surface on the vitreous side 
of the ILM and only sparse vitreous remnants 
were seen in two other eyes. In contrast only 3 
control eyes showed a smooth ILM surface. This 
study along with other similar reports showed 
that remnants of vitreous strands are more 
effectively eliminated from the inner surface of 
the ILM with plasmin assisted vitrectomy.34-36
There are several studies evaluating 
autologous plasmin for macular hole surgery. 
Although there is no randomized clinical trial 
comparing macular hole closure rates and 
complications of vitrectomy with and without 
plasmin, multiple small case series suggest that 
plasmin facilitates vitreous surgery.26-28,37 In a 
retrospective study, Wu et al27 reported the 
results of autologous plasmin enzyme assisted Pharmacologic Vitreolysis; Nazari et al
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vitrectomy on 13 pediatric patients aged 1-15 
years with a traumatic macular hole. The 
macular hole was closed successfully in 12 cases 
and they proposed that autologous plasmin 
may be a helpful adjunct during vitrectomy 
for traumatic macular holes.
Hirata and colleagues29 evaluated the 
feasibility of autologous plasmin for surgical 
treatment in six patients with bilateral PDR. 
They used autologous plasmin in one eye of each 
patient and compared the fellow eyes in terms 
of surgical time and incidence of retinal tears. 
Both surgical time (68 versus 89 minutes, P=0.04) 
and incidence of retinal tear (nil versus 3 eyes) 
were significantly lower in the plasmin group. 
Moreover, no additional surgical procedures for 
removing the proliferative membrane including 
delamination or segmentation were needed 
in the plasmin group. However, there was no 
significant difference between the two groups 
regarding final visual outcomes.
Tsukahara et al32 reported six consecutive 
eyes of four premature infants with stage 5 
retinopathy of prematurity (ROP). Four eyes 
showed retinal detachment with closed funnel 
configuration. After lensectomy and dissection 
of anterior proliferative membranes, 0.03 to 0.22 
IU autologous plasmin was administered into 
the vitreous cavity. Fifteen to 30 minutes later, 
the proliferative membranes were successfully 
removed without causing iatrogenic breaks in 
all eyes. Complete reattachment of the posterior 
pole was achieved in all six eyes. No obvious 
complication was observed during the follow-
up period, which ranged from 11 to 14 months.
In a large case series reported by Wu et al,33 
80 eyes with stage 5 ROP underwent vitreoretinal 
surgery using autologous or maternal plasmin. 
Fifty-three eyes had previously undergone 
vitrectomy with or without retinal breaks. 
Following surgery for all 80 eyes, anatomic 
success was achieved in 68.8% of the cases, 
in contrast to 23% to 59% in previous reports. 
The authors concluded that plasmin-assisted 
vitrectomy in eyes with advanced ROP with 
or without previous vitrectomy increases the 
chance of anatomical and visual improvement.
Diaz-Llopis and colleagues38 reported their 
experience with low dose intravitreal autologous 
plasmin injection in lieu of vitrectomy for 
treatment of patients with refractory diabetic 
macular edema. Intravitreal plasmin was 
injected in one eye of 16 patients with refractory 
diffuse diabetic macular edema and the fellow 
eyes served as controls. One month after 
injection, central macular thickness (CMT) was 
reduced and best-corrected visual acuity (BCVA) 
increased significantly in plasmin injected eyes. 
BCVA and CMT were stable up to 6 months. 
The authors proposed that intravitreal plasmin 
injection effectively reduces macular thickness 
and improves vision in diabetic patients with 
macular edema refractory to conventional laser 
treatment. They did not report the condition 
of the vitreoretinal interface in their patients.
In most of the above-mentioned reports, 
plasmin was derived preoperatively from 
the patient’s blood. The most commonly 
used technique is affinity chromatography. 
Plasminogen obtained by this technique is 
concentrated and converted by a plasminogen 
activator to plasmin. The plasmin should pass 
sterility controls and be refrigerated prior 
to use.39 This technique is time consuming, 
cumbersome and difficult. An easier technique 
has been described which involves centrifuging 
autologous blood for separating plasminogen 
containing plasma followed by activating 
plasminogen with streptokinase or urokinase.40 
Plasmin is not commercially available for clinical 
use as mentioned earlier, furthermore enzyme 
activity is dependent on several variables 
including plasminogen level in the blood. 
Therefore plasmin has not gained widespread 
use for vitrectomy surgery.41
Microplasmin
The development of recombinant microplasmin 
solved most of the problems of autologous 
plasmin. Microplasmin contains only the 
enzymatic portion of the plasmin molecule while 
the other domains are omitted.42 This makes 
the microplasmin molecule much smaller than 
the original molecule (28 KD vs 80 KD) with 
the same enzymatic activity. Microplasmin has 
been shown to induce vitreous liquefaction and 
PVD without any evidence of retinal toxicity.10 Pharmacologic Vitreolysis; Nazari et al
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Sakuma et al10 injected different doses of 
microplasmin into rabbit eyes and showed that 
intravitreal injection of microplasmin causes no 
electroretinographic or ultrastructural retinal 
abnormalities. Doses greater than 125 μg 
induced complete PVD. The authors suggested 
that microplasmin may be a useful adjunct to 
vitreous surgery or could be used to induce PVD 
without vitreous surgery. Chen et al42 have also 
shown that microplasmin is able to induce PVD 
without retinal toxicity in rabbit eyes.
de Smet and colleagues43 have recently 
shown that PVD induction by microplasmin is 
both dose and time dependent in porcine eyes. 
One hour after injection, the posterior pole was 
detached in 100% of the eyes with 125 μg of 
microplasmin but the midperipheral vitreous 
was also detached using the 250 μg dosage. 
Vitreous at the ora however, was not detached. 
After 2 hours of exposure, midperipheral 
detachment was observed with the 125 μg dose 
as well. A smooth retinal surface was seen at 
the site of enzyme induced PVD. They found 
the minimum effective dose to be 125 μg.
In a recent animal study, Sebag et al44 
reported that pharmacologic vitreolysis with 
recombinant microplasmin increased vitreous 
diffusion coefficient as determined with 
dynamic light scattering. This could result 
in metabolic changes in the retina. Quiram 
and colleagues45 recently reported that PVD 
induction by microplasmin increases oxygen 
level in the vitreous cavity.
de Smet et al46 have published the results 
of MIVI I (Microplasmin for Intra Vitreous 
Injection) trial. In this multicenter, prospective, 
uncontrolled, dose-escalation, phase I/II clinical 
trial, the safety and preliminary efficacy of 4 
doses and several exposure times of intravitreal 
microplasmin given before vitrectomy for 
vitreomacular traction maculopathy were 
evaluated. A single intravitreal injection of 4 
different doses (25, 50, 75, or 125 μg in 100 μl) 
of microplasmin was administered 1 to 2 hours, 
24 hours, or 7 days before planned pars plana 
vitrectomy. Increasing doses and incubation 
times resulted in an increased rate of PVD in 
some patients. They proposed that although the 
drug is well tolerated and capable of inducing 
pharmacologic PVD in some patients, larger, 
controlled trials are warranted. At the present, 
ThromboGenics, a Belgium based pharmaceutical 
company, provides microplasmin commercially.
Nattokinase
Nattokinase, a strong fibrinolytic agent, was 
originally derived from natto which is a 
popular soybean cheese in Japan.11 Nattokinase 
(subtilisin NAT) is a serine protease composed 
of 275 amino acids produced by Bacillus subtilis 
(natto). It can be administered orally and is 
present in foods prepared from fermented 
soybean. Because of its potent fibrinolytic effect 
it is now under investigation for prevention of 
cardiovascular thrombotic events and reducing 
blood pressure.47,48 Takano et al11 injected 0.1 
and 1 fibrin-degradation unit (FU) of nattokinase 
into rabbit eyes and showed that both doses 
could produce complete PVD with a smooth 
inner ILM surface, but the higher dose (1 FU) 
was associated with some retinal toxicity. More 
investigations are needed to clarify the safety 
and efficacy aspects of this new vitreolytic agent.
Chondroitinase
Hermel and Schrage49 investigated the efficacy of 
human and porcine plasmin and chondroitinase 
in creating vitreoretinal separation in the pig 
eye. Chondroitinase (1 U) failed to increase PVD 
rates in pig eyes after 1 hour of incubation, but 
spontaneous PVD occurred more frequently and 
to a larger extent in plasmin treated eyes than 
placebo controls. Chondroitinase also failed to 
produce any effect on the vitreoretinal interface 
but in plasmin-treated eyes, scanning electron 
microscopy showed a smooth ILM surface free 
from vitreous remnants. Staubach et al50 injected 
plasmin, hyaluronidase and chondroitinase into 
freshly enucleated pig eyes. All enzymes showed 
increased vitreous removal rates, however 
chondroitinase was the weakest.
Dispase
Dispase is a protease which was studied for 
induction of PVD in one of the earliest animal Pharmacologic Vitreolysis; Nazari et al
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studies in this field. Tezel et al51 injected dispase 
into human and porcine cadaver eyes. After 
15 minutes of incubation, partial or total PVD 
was seen in the majority of enucleated porcine 
and human eyes. Microscopic examination 
demonstrated that dispase cleaved the 
attachment between the posterior hyaloid and 
the ILM with minimal damage to the inner 
retina. Retinal cell viability and the mechanical 
properties of the retina were similar in dispase-
treated and control eyes. They concluded that 
the enzyme may be useful in removing cortical 
vitreous during vitreous surgery. While some 
studies have shown that dispase is useful for 
PVD induction,52 most experimental studies 
have indicated some harmful effects.53-55
Dispase is a proteolytic enzyme and 
dissociates tissues, therefore it has been suggested 
that intraocular injection of dispase could trigger 
events leading to proliferative vitreoretinopathy 
(PVR). Frenzel et al56 injected dispase into rabbit 
eyes and showed that it initiated the development 
of PVR without addition of exogenous cells, 
growth factors, or cytokines typically found 
in PVR membranes. A cascade of events was 
probably triggered by dispase, causing native cells 
and factors to produce PVR. Other investigators 
have shown that intravitreal dispase can result 
in cataracts and lens subluxation as well as 
reproducible induction of PVR.57
Hyaluronidase
While other vitreolytic agents act by separating 
the vitreoretinal interface, hyaluronidase exerts 
its effect by dissolving the glycosaminoglycan 
network of the vitreous gel which is predominantly 
composed of hyaluronan. Collagen fibrils of 
the vitreous are very resistant to proteolytic 
degradation and therefore not a good target 
for pharmacological vitreolysis, but enzymatic 
degradation of the hyaluronan helps vitreous 
degradation and thus may facilitate dispersal of 
vitreous hemorrhage.58 Some studies has shown 
that intravitreal injection of hyaluronidase could 
increase the rate of vitreous removal during 
vitrectomy.50
Highly purified bovine hyaluronidase 
(Vitrase) is the only vitreolytic agent that has 
passed phase III trials.59 Hyaluronidase basically 
acts on the glycoside bonds of hyaluronan and 
other mucopolysaccharides in the vitreous 
and causes vitreous liquefaction.20 There 
is no evidence to support a direct effect of 
hyaluronidase on the vitreoretinal interface. 
Vitrase was evaluated in two phase III trials 
for management of vitreous hemorrhage.60
A total of 1,125 patients were randomized 
in a 1:1:1 ratio to intravitreal injection of saline 
and 55 IU or 75 IU of hyaluronidase. The 
primary end point was clearance of vitreous 
hemorrhage. There was a statistically significant 
improvement in the 55 IU group at 1, 2 and 
3 months as compared to the saline group. 
Intravitreal injection of hyaluronidase was well 
tolerated without any significant complication.60 
Although the study investigators concluded 
that intravitreal hyaluronidase was useful in 
the management of vitreous hemorrhage, this 
agent has not yet received FDA approval for 
this indication. Furthermore, other studies have 
shown that although hyaluronidase may help in 
vitreous liquefaction and vitreous hemorrhage 
clearance, it does not induce vitreoretinal 
separation.20
Zhi-Liang and colleagues61 evaluated intra-
vitreal injection of plasmin, hyaluronidase, 
combined plasmin and hyaluronidase, and BSS to 
induce PVD in diabetic rat eyes. Hyaluronidase 
alone was ineffective, whereas plasmin alone 
induced partial PVD, a potentially dangerous 
condition for diabetic eyes. However, the 
combination of hyaluronidase and plasmin 
induced complete PVD in diabetic rats. PVD 
induction was more difficult in diabetic rats than 
in healthy rats. Wang et al20 showed that vitreous 
injection of plasmin and hyaluronidase induced 
complete PVD with no obvious toxicity; plasmin 
induced partial PVD, but hyaluronidase had 
no effect. It has also been commented that the 
combination of plasmin and hyaluronidase is not 
necessary and an appropriate dose of intravitreal 
plasmin alone can induce complete PVD.62
FuTuRE HORIZONS
Sutureless vitrectomy using the 23 or 25 gauge 
systems has gained increasing popularity in Pharmacologic Vitreolysis; Nazari et al
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recent years. One of the main concerns in 
small gauge vitrectomy is the decreased rate of 
vitreous removal by smaller vitrectomy probes. 
Hermel and associates63 measured the volume 
of vitreous removed by the vitreous cutter at 
pre-specified time intervals in rabbit eyes with 
and without plasmin incubation. They found 
that intravitreal plasmin injection could increase 
the rate of vitreous removal which showed a 
linear correlation with incubation time. It may 
be concluded from this study, as well as those 
mentioned earlier, that vitreolytic agents may 
facilitate vitrectomy and reduce operative time.
Enzyme-induced PVD in animal models 
increases lens nucleus oxygen levels. There 
may also be some correlation between the 
presence of PVD and the rate of nuclear cataract 
progression in humans.64 The effect of vitreolytic 
agents in the progression of cataract needs to 
be elaborated. Pharmacologic PVD induction 
and the ensuing increased vitreous oxygen 
levels may also have some effect on AMD and 
retinal ischemic diseases.44,45 The possible role 
of plasmin in stimulation of PVR should be 
further evaluated. If this is proven to be the 
case, antiplasmin agents may have a role in 
the future management of PVR.65
CONCLuSION
Creating a complete and atraumatic vitreoretinal 
separation and attaining an ultrastructurally 
smooth and vitreous-free ILM surface is an 
essential step for successful vitreoretinal surgery. 
This may also improve retinal oxygenation and 
decrease the risk of PVR. Although multiple 
agents have been studied, recent reports on the 
beneficial effects of plasmin and microplasmin 
have raised strong hopes that pharmacologic 
vitreolysis may eventually find its way to clinical 
practice. Further investigations will demonstrate 
whether enzymatic vitreolysis could be used 
as an adjunct and/or alternative treatment for 
treatment of vitreoretinal disorders.
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